Ye R, Kim J H, Kim B G, Szarka S, Sihota E, Wong S L
Department of Biological Sciences, Division of Cellular, Molecular and Microbial Biology, University of Calgary, 2500 University Drive, N.W., Calgary, Alberta T2N 1N4, Canada.
Biotechnol Bioeng. 1999 Jan 5;62(1):87-96.
Staphylokinase is a promising blood-clot dissolving agent for the treatment of patients suffering from a heart attack. It would be desirable to produce this protein in large quantities for biochemical characterization and clinical trials. Production of intact, biologically active staphylokinase from bacterial expression systems has been a challenge because of N-terminal microheterogeneity, plasmid instability, or low-production yield. By using a seven-extracellular-protease deficient Bacillus subtilis strain, WB700, intact staphylokinase can be produced via secretion. However, native staphylokinase gene (sak) in a high-copy number plasmid was found to be unstable in B. subtilis. To optimize the production and the stability of the expression vectors, both the promoter and the signal sequence of sak were replaced by B. subtilis promoters (P43, a constitutively expressed promoter; Pamy, a stationary-phase promoter; and PsacB, a sucrose-inducible promoter) and the levansucrase-signal sequence, respectively. This overcame the plasmid instability problem. To enhance transcription from the sacB promoter, degQ encoding a transcriptional activator for sacB and other protease genes was also installed in the expression vector. The use of WB700 as the expression host allowed enhanced production of staphylokinase from the sucrose-inducible plasmid without causing any obvious degradation of staphylokinase. Both the P43 and PsacB (with DegQ) promoters worked well. Over 90% of staphylokinase synthesized can be secreted effectively. With the optimization of both the culture media and the fermentation conditions, production of staphylokinase reached a level of 337 mg/L, and staphylokinase could be purified to homogeneity by a simple three-step purification scheme. Secreted staphylokinase did not show any N-terminal heterogeneity. This presents an attractive system for the production of staphylokinase in both high quality and quantity.
葡萄球菌激酶是一种很有前景的溶栓剂,可用于治疗心脏病发作患者。大量生产这种蛋白质以进行生化特性分析和临床试验将是很有必要的。由于N端微异质性、质粒不稳定性或低产量,从细菌表达系统中生产完整的、具有生物活性的葡萄球菌激酶一直是一项挑战。通过使用一种缺乏七种细胞外蛋白酶的枯草芽孢杆菌菌株WB700,可以通过分泌产生完整的葡萄球菌激酶。然而,发现高拷贝数质粒中的天然葡萄球菌激酶基因(sak)在枯草芽孢杆菌中不稳定。为了优化表达载体的生产和稳定性,分别用枯草芽孢杆菌启动子(P43,一种组成型表达启动子;Pamy,一种稳定期启动子;和PsacB,一种蔗糖诱导型启动子)和果聚糖蔗糖酶信号序列替换了sak的启动子和信号序列。这克服了质粒不稳定性问题。为了增强来自sacB启动子的转录,编码sacB和其他蛋白酶基因转录激活因子的degQ也被安装在表达载体中。使用WB700作为表达宿主能够提高从蔗糖诱导型质粒中生产葡萄球菌激酶的产量,而不会导致葡萄球菌激酶有任何明显的降解。P43和PsacB(带有DegQ)启动子都表现良好。合成的葡萄球菌激酶中有超过90%能够有效分泌。通过优化培养基和发酵条件,葡萄球菌激酶的产量达到了337 mg/L的水平,并且可以通过简单的三步纯化方案将葡萄球菌激酶纯化至同质。分泌的葡萄球菌激酶没有显示出任何N端微异质性。这为高质量和高产量生产葡萄球菌激酶提供了一个有吸引力的系统。